NCT05536401

Brief Summary

This study is a prospective comparative, randomized, single center study to assess agreement and precision of the P200TE in comparison to the predicate device in normal subjects, subjects with glaucoma, and subjects with retinal disease.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 2, 2022

Completed
5 days until next milestone

First Submitted

Initial submission to the registry

September 7, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 10, 2022

Completed
10 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2022

Completed
Last Updated

November 17, 2022

Status Verified

November 1, 2022

Enrollment Period

18 days

First QC Date

September 7, 2022

Last Update Submit

November 14, 2022

Conditions

Outcome Measures

Primary Outcomes (8)

  • Limit of Agreement (LOA) between the P200TE and predicate device measurements of full retinal thickness.

    1 year

  • Limit of Agreement (LOA) between the P200TE and predicate device measurements of retinal nerve fiber layer thickness (μm).

    1 year

  • Limit of Agreement (LOA) between the P200TE and predicate device measurements of ganglion cell complex thickness (μm).

    1 year

  • Limit of Agreement (LOA) between the P200TE and predicate device measurements of optic disc (disc area, rim area, cup-to-disc area, cup-to-disc vertical, cup-to-disc horizontal)

    1 year

  • Precision between the P200TE and predicate device measurements of full retinal thickness.

    1 year

  • Precision between the P200TE and predicate device measurements of retinal nerve fiber layer thickness.

    1 year

  • Precision between the P200TE and predicate device measurements of ganglion cell complex thickness

    1 year

  • Precision between the P200TE and predicate device measurements of optic disc (disc area, rim area, cup-to-disc area, cup-to-disc vertical, cup-to-disc horizontal)

    1 year

Study Arms (1)

Optical Coherence Tomography (OCT)

OTHER
Device: P200TEDevice: Predicate Device

Interventions

P200TEDEVICE

The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.

Optical Coherence Tomography (OCT)

The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.

Optical Coherence Tomography (OCT)

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects 22 years of age or older on the date of informed consent
  • Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  • Subjects with normal eye examinations in both eyes on the date of the study visit as observed with a 90 diopter lens
  • BCVA 20/40 or better (each eye) on the date of the study visit

You may not qualify if:

  • Subjects unable to tolerate ophthalmic imaging
  • Subjects not able to obtain acceptable OCT images due to ocular media opacity or other reasons
  • Subject has a condition or is in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
  • Presence of any ocular pathology except for cataract in either eye
  • Subjects 22 years of age or older on the date of informed consent
  • Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  • BCVA 20/40 or better in the study eye
  • History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:
  • On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
  • Glaucoma hemi-field test "outside normal limits."
  • Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:
  • Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;
  • Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
  • Subjects unable to tolerate ophthalmic imaging
  • Subjects not able to obtain acceptable OCT images due to ocular media opacity or other reasons
  • +12 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Illinois College of Optometry

Chicago, Illinois, 60616, United States

Location

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 7, 2022

First Posted

September 10, 2022

Study Start

September 2, 2022

Primary Completion

September 20, 2022

Study Completion

September 20, 2022

Last Updated

November 17, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations